Use your specific donor whether it be HLA matching or engineered cells for immuno-oncology studies using CD34+ humanized NSG™ mice.
NSG™ mice engrafted with CD34+ hematopoietic stem/progenitor cells (HSPCs) are an attractive model for immune-oncology efficacy studies, as they are a validated platform that provides bone marrow engraftment with development of multi-lineage human immune cells in the peripheral blood. However, the CD34+ donors are typically selected by the mouse provider rather than by the customer. For many studies, such as those with engineered cells (e.g. HSPCs and CAR-T), it may be preferential that the study sponsor dictates the donor for CD34+ humanization in NSG mice. Hera has demonstrated through effective recipient conditioning, transplantation and flow cytometric (FC) analysis efficient engraftment of engineered CD34+ HSPCs as indicated by high levels of human CD45+ chimerism in the blood and bone marrow.